Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
8.0
来源：
Cell
发布时间：
2025-08-26 16:02
摘要：
This study explores a novel T cell engineering strategy to enhance anti-tumor immunity by promoting dendritic cell (DC) recruitment and T cell activation through the expression of Flt3L and XCL1. The engineered T cells demonstrated superior efficacy in murine models, significantly improving tumor control and eliciting robust polyclonal T cell responses. The findings suggest that optimizing DC-T cell interactions can enhance the effectiveness of CAR-T therapies against solid tumors, addressing challenges such as antigen heterogeneity and immune evasion.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.0分
technical_barrier_competition
0.5分
关键证据
FX-engineered T cells trigger robust antigen spreading and potent endogenous polyclonal T cell response.
The therapeutic efficacy of FX-armed CAR-T cells is validated in murine models.
XCL1 expression positively correlates with CD8+ Tpex signature and patient response to ICB.
真实性检查
否
AI评分总结
This study explores a novel T cell engineering strategy to enhance anti-tumor immunity by promoting dendritic cell (DC) recruitment and T cell activation through the expression of Flt3L and XCL1. The engineered T cells demonstrated superior efficacy in murine models, significantly improving tumor control and eliciting robust polyclonal T cell responses. The findings suggest that optimizing DC-T cell interactions can enhance the effectiveness of CAR-T therapies against solid tumors, addressing challenges such as antigen heterogeneity and immune evasion.